Listed

Relmada Therapeutics, Inc.: Form 10-K for the period ended Jun 30, 2017

Filed with the SEC on Sep 28, 2017 and accepted by EDGAR at Sep 28, 2017, 16:42 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2017-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development12 months2016-07-01 to 2017-06-30$1.3mus-gaap:ResearchAndDevelopmentExpense
Operating income12 months2016-07-01 to 2017-06-30−$7.2mus-gaap:OperatingIncomeLoss
Net income12 months2016-07-01 to 2017-06-30−$6.3mus-gaap:NetIncomeLoss
Diluted EPS12 months2016-07-01 to 2017-06-30−$0.52us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow12 months2016-07-01 to 2017-06-30−$6.5mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure12 months2016-07-01 to 2017-06-30$49.7kus-gaap:PaymentsToAcquireProductiveAssets
Cash and equivalentsAt period end2017-06-30$1.7mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2017-06-30$2.5mus-gaap:AssetsCurrent
Total assetsAt period end2017-06-30$2.8mus-gaap:Assets
Current liabilitiesAt period end2017-06-30$1.4mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2017-06-30$1.4mus-gaap:Liabilities
Shareholders' equityAt period end2017-06-30$1.5mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001213900-17-010097. Last ingested by Listed: Nov 13, 2026, 15:42 ET. Listed shows no prices and gives no investment advice.